期刊文献+

直肠癌同时性肝转移的外科治疗 被引量:4

Surgical treatment of rectal cancer with synchronous hepatic metastases
下载PDF
导出
摘要 目的探讨直肠癌同时性肝转移外科治疗手术时机及方法。方法对2006年8月至2008年8月在我中心32例直肠癌同时性肝转移患者的诊断和治疗的临床资料进行回顾性分析。结果术前B超、CT、MRI能够明确诊断直肠癌肝转移灶能否手术切除;术前新辅助化疗及靶向治疗可以进一步筛选直肠癌肝转移;治疗模式是以手术为主的综合性治疗。结论可切除的直肠癌肝转移首选手术治疗;采取合适的、个体化综合治疗手段能够提高无瘤生存率和累计生存率。 Objective To investigate the surgical occasion and approach of rectal cancer with synchronous hepatic metastases.Methods Retrospective analysis was conducted on the clinical data of 32 patients who had been diagnosed as rectal cancer with synchronous hepatic metastases.Results The resectability of hepatic metastasis site from rectal cancer for the patient could be exactly diagnosed by type-B ultrasonic,computer tomography(CT) and magnetic resonance imaging(MRI) before surgical operation.Neo-adjuvant chemotherapy and targeted therapy would aid a lot in the further filter of patients who had been diagnosed as rectal cancer with synchronous hepatic metastases.Comprehensive therapy which mainly based on surgical was adopted.Conclusion Surgical treatment was still the first choice for the patients with resectable rectal cancer with synchronous hepatic metastases.Appropriate subject-specific comprehensive therapy could improve the disease free survival rate and accumulated survival rate.
出处 《临床肝胆病杂志》 CAS 2012年第1期17-20,共4页 Journal of Clinical Hepatology
基金 吉林省科技厅项目(200705249)
关键词 直肠肿瘤 肿瘤转移 新辅助化疗 靶向治疗 rectal neoplasms neoplasm metastasis neo-adjuvant chemotherapy,targeted therapy
  • 相关文献

参考文献5

二级参考文献59

  • 1GregoryBMakin,DavidJBreen,JohnRTMonson.The impact of new technology on surgery for colorectal cancer[J].World Journal of Gastroenterology,2001,7(5):612-621. 被引量:21
  • 2秦新裕,许剑民,刘凤林,钟芸诗.进展期消化道肿瘤术前介入治疗的评价[J].中国实用外科杂志,2005,25(5):307-309. 被引量:13
  • 3Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable coloreetal liver metastases [J]. Ann Surg Oncol, 2009, 16(9): 2385-2390.
  • 4Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer [J]. Curr Opin Oncol, 2010, 22(4): 364-373.
  • 5Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy [J]. J Clin Oncol, 2009, 27(22): 3677-3683.
  • 6Gallagher D, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure [J]. Oncotogy, 2010, 78 (3-4) : 237-248.
  • 7Choti M. Controversies in the management of hepatic colorectalmetastases [J]. Ann Surg Oncol, 2009, 16(9): 2383- 2384.
  • 8Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increase postoperative liver insufficiency after hepatic reset tion for colorectal liver metastases [J]. Ann Surg Oncol, 2010, 17(11): 2870-2876.
  • 9Adam R, Hailer DG, Poston G, et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the international congress on anti-cancer treatment (ICACT) 2009 [J]. Ann Oncol, 2009, 21(8): 1579-1584.
  • 10Nordlinger B, Cutsem E, Greuenberger B, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel [J]. Ann Oncol, 2009, 20(6): 985-992.

共引文献31

同被引文献26

  • 1熊壮,王建华,颜志平,钱晟,刘嵘,周大勇.胃肠道肿瘤肝转移介入治疗的临床研究[J].中国医学计算机成像杂志,2007,13(2):120-123. 被引量:9
  • 2Aune D,Chan DS,Lau R,et al.Dietary fibre,wholegrains,and risk of colorectal cancer:systematic review anddose-response meta-analysis of prospective studies[J].BMJ,2011,343:d6617.
  • 3Pitule P,Liska V,Treska V,et al.Contribution of molecularbiology to the diagnosis and therapy of colorectal carcinoma-thepresent and future[J].Rozhl Chir,2011,90(6):315-323.
  • 4Mathivanan S,Lim JW,Tauro BJ,et al.Proteomics analysisof A33immunoaffinity purified exosomes released from thehuman colon tumor cell line LIM1215reveals a tissue-specificprotein signature[J].Mol Cell Proteomics,2010,9(2):197-208.
  • 5Batista BS,Eng WS,Pilobello KT,et al.Identification of aconserved glycan signature for microvesicles[J].J ProteomeRes,2011,10(10):4624-4633.
  • 6Zhong H,Yang Y,Ma S,et al.Induction of a tumour-specific CTL response by exosomes isolated from heat-treatedmalignant ascites of gastric cancer patients[J].Int JHyperthermia,2011,27(6):604-611.
  • 7Yang C,Kim SH,Bianco NR,et al.Tumor-derivedexosomes confer antigen-specific immuno-suppression in amurine delayed-type hypersensitivity model[J].PLoS One,2011,6(8):e22517.
  • 8Taylor DD,Gercel-Taylor C.Exosomes/microvesicles:mediators of cancer-associated immunosuppressivemicroenvironments[J].Semin Immunopathol,2011,33(5):441-454.
  • 9Sheng H,Hassanali S,Nugent C,et al.Insulinoma-releasedexosomes or microparticles are immunostimulatory and canactivate autoreactive T cells spontaneously developed innonobese diabetic mice[J].J Immunol,2011,187(4):1591-1600.
  • 10Escrevente1C,Keller S,Altevogt P,et al.Interaction anduptake of exosomes by ovarian cancer cells[J].2011,11(1):108-117.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部